AZ SB1542

Requires employers to provide workers' compensation coverage for firefighters and certified peace officers diagnosed with PTSD, potentially including one complete course of midomafetamine (MDMA) treatment if deemed necessary by an independent medical examination and prescribed by a psychiatrist.

Appropriates $10,000,000 from the state general fund in fiscal year 2026-2027 to the Department of Health Services for grants supporting clinical trials, research, and clinician training on midomafetamine treatment for PTSD in first responders and veterans.

Allows any 3,4-methylenedioxymethamphetamine (MDMA) compound approved by the FDA and rescheduled by the DEA from Schedule I to be prescribed as a controlled substance in Arizona.

Makes key provisions conditional on FDA approval of midomafetamine for PTSD treatment by January 1, 2029, with the research funding provision contingent on FDA approval by January 1, 2027.

Requires the Industrial Commission to submit annual reports on midomafetamine treatment costs and to establish reimbursement values and billing guidelines once FDA approval occurs.